Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2026 | Design and aim of the HYPORT study in regional nodal breast cancer

Sanjoy Chatterjee, MBBS, Tata Medical Center, Kolkata, India, presents the background for the HYPORT study (NCT03788213), a randomized, controlled trial of ultra hypofractionated radiotherapy across 5 fractions compared with moderately hypofractionated radiotherapy across 15 fractions in regional nodal breast cancer patients. The study aims to compare the tolerability and quality of life experienced by patients receiving the two treatments. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.